What are you looking for?

Dr. Joanne Hulme currently serves as Chief Scientific Officer of Radiant Biotherapeutics, an innovative antibody platform company developing multi-valent and multi-specific biotherapeutics with broad transformative applications.  Prior to Radiant Biotherapeutics, she was VP, Head of Research for Northern Biologics, where she developed first-in-class antibody therapeutics in cancer and fibrotic diseases.  Prior to Northern, Dr. Hulme previously worked at Amgen, where her research resulted in the development of multiple preclinical programs in autoimmune diseases and cancer.    Dr. Hulme earned her Ph.D. in Pharmacology from the University of Leeds.

Increasing valency is a promising approach to improve potency and addresses biology not easily accessible with current antibody approaches.  Radiant’s proprietary MultabodyTM technology leverages avidity – stronger binding power – coupled with multi-specificity and right geometry to deliver breakthrough therapeutics with broad transformative potential.  This innovative approach aims to break the deadlock on valency constrained biology to unlock TNFR receptor agonism to precisely control clustering and deliver superior efficacy and safety.  It’s lead oncology program, RBT-101, a multivalent 4-1BB agonist, has demonstrated robust and durable preclinical efficacy without the liver toxicity of prior approaches and is advancing towards clinical development.  Through rational design, the MultabodyTM platform is also being deployed to unlock the worlds most persistent infectious diseases achieving unprecedented neutralization and breadth unattainable by antibody cocktails.  Together, Multabodies represent a breakthrough antibody approach that combines multivalency, multispecificity and geometry to deliver innovative therapeutics in oncology and beyond.